In a former study of our group, we demonstrated that in long-term anti-TNF-α infliximab-treated RA patients, the intravenous infusion of this monoclonal antibody yielded a significant rapid but transient improvement of endothelial dysfunction [25]. The gene discussed is TNF; the disease is rheumatoid arthritis.